2017
Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies
SEVCIKOVA, Tereza, Katerina GROWKOVA, Zuzana CHYRA, Jana FILIPOVA, P. VRUBLOVA et. al.Základní údaje
Originální název
Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies
Autoři
SEVCIKOVA, Tereza (203 Česká republika), Katerina GROWKOVA (203 Česká republika), Zuzana CHYRA (203 Česká republika, domácí), Jana FILIPOVA (203 Česká republika), P. VRUBLOVA (203 Česká republika), Tomas JELINEK (203 Česká republika), Z. KORISTEK (203 Česká republika), F. KRYUKOV (203 Česká republika), Elena Vladimirovna KRYUKOVA (203 Česká republika, garant, domácí) a Roman HÁJEK (203 Česká republika)
Vydání
Journal of clinical pathology, London, BMJ Publishing Group, 2017, 0021-9746
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30109 Pathology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.894
Kód RIV
RIV/00216224:14110/17:00100122
Organizační jednotka
Lékařská fakulta
UT WoS
000411180200006
Klíčová slova anglicky
monoclonal gammopathies; MULTIPLE-MYELOMA; BONE-MARROW; PLASMA-CELLS; CRITERIA; DISEASE; RNA
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 1. 2020 16:21, Mgr. Marie Šípková, DiS.
Anotace
V originále
Aims Some types of monoclonal gammopathies are typified by a very limited availability of aberrant cells. Modern research use high throughput technologies and an integrated approach for detailed characterisation of abnormal cells. This strategy requires relatively high amounts of starting material which cannot be obtained from every diagnosis without causing inconvenience to the patient. The aim of this methodological paper is to reflect our long experience with laboratory work and describe the best protocols for sample collection, sorting and further preprocessing in terms of the available number of cells and intended downstream application in monoclonal gammopathies research. Potential pitfalls are also discussed. Methods Comparison and optimisation of freezing and sorting protocols for plasma cells in monoclonal gammopathies, followed by testing of various nucleic acid isolation and amplification techniques to establish a guideline for sample processing in haemato-oncology research. Results We show the average numbers of aberrant cells that can be obtained from various monoclonal gammopathies (monoclonal gammopathy of undetermined significance/light chain amyloidosis/multiple myeloma (MM)/MM circulating plasma cells/minimal residual disease MM-10 123/22 846/305 501/68 641/4000 aberrant plasma cells of 48/30/10/16/37x106 bone marrow mononuclear cells) and the expected yield of nucleic acids provided from multiple isolation kits (DNA/RNA yield from 1 to 200x10(3) cells was 2.14-427/0.12-123 ng). Conclusions Tested kits for parallel isolation deliver outputs comparable with kits specialised for just one type of molecule. We also present our positive experience with the whole genome amplification method, which can serve as a very powerful tool to gain complex information from a very small cell population.